Destiny Pharma to Join Equity Development Webinar on
Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001)
No treatment related adverse events
Brighton, United Kingdom – 29th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that the Company’s management team will host a live presentation on Tuesday 30th March at 3:30pm BST with Equity Development.